Contemporary risk assessment and risk-reducing strategies for tubo-ovarian cancer in women with BRCA pathogenic variants
- 3 April 2026
- journal article
- review article
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (6) , 104676
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- University of Texas MD Anderson Cancer Center
This publication has 61 references indexed in Scilit:
- Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US WomenJAMA Oncology, 2025
- Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJAMA Oncology, 2024
- Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant CarriersJAMA Oncology, 2021
- The fallopian tube as origin of ovarian cancer: Change of diagnostic and preventive strategiesCancer Medicine, 2019
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA MutationsJAMA Oncology, 2016
- Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian CancerJAMA, 2015
- Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriersInternational Journal of Cancer, 2014
- Effect of Screening on Ovarian Cancer MortalityJAMA, 2011
- Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancerThe Journal of Pathology, 2001